« January 2009 »
S M T W R F S
1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

Home About Us Research Projects Group Members Publications Contact Us
News Blog Links of Interest

Publications


Reprint Request Form
Your Name
Your E-Mail
Institution

Book Chapters

Request Link Book Chapter
Young LJ, Owens MJ and Nemeroff CB. 2008. Neuropeptides: biology, regulation and role in neuropsychiatric disorders. Comprehensive Textbook of Psychiatry, 9th edition (BJ Kaplan and VA Sadock, Eds.), Lippincott Williams and Wilkins, Baltimore, pp. 85-96.
Owens MJ and Ritchie JC. 2004. Clinical neurochemistry. Neurobiology of Mental Illness, 2nd edition (DS Charney, EJ Nestler and BS Bunney, Eds.), Oxford University Press, New York, pp. 141-154.
Owens MJ and Risch SC. 2001. Atypical antipsychotics. Essentials of Clinical Psychopharmacology (AF Schatzberg and CB Nemeroff, Eds.), American Psychiatric Association Press, Washington, DC, pp 125-154.
Nemeroff CB and Owens MJ. 2001. Contribution of modern neuroscience to developing new treatments for psychiatric disorders in the 21st century. Treatment of Depression: Bridging the 21st Century (MM Weissman, ed.), American Psychiatric Press, Washington DC, pp 61-81.
Owens MJ, Mulchahey JJ and Plotsky PM. 1996. Molecular and neurobiological mechanisms in the treatment of psychiatric disorders. Psychiatry (A Tasman, J Kay and JA Lieberman, Eds.), WB Saunders Co., Philadelphia, pp. 210-257.

Research Reviews

Request Link Research Review
McConathy J and Owens MJ. 2003. Stereochemistry and drug action. J. Clinical Psychiatry ? Primary Care Companion 5:70-73.
Nemeroff CB and Owens MJ. 2002. Treatment of mood disorders. Nature Neuroscience 5(suppl):1068-1070.
Owens MJ and Rosenbaum JF. 2002. Escitalopram: a second generation SSRI. CNS Spectrums 7(4S1):34-39, 2002.
Binder E, Kinkead B, Owens MJ and Nemeroff CB. 2001. Neurotensin-dopamine interactions. Pharmacological Reviews 53:453-486.
Stout SC, Owens MJ and Nemeroff CB. 2001. Neurokinin1 receptor antagonists as potential antidepressants. Annual Reviews in Pharmacology & Toxicology 41:877-906.
Owens MJ and Nemeroff CB. 1999. Corticotropin releasing factor antagonists in affective disorders. Expert Opinions on Investigational Drugs 8:1849-1858.
Owens MJ and Nemeroff CB. 1999. Corticotropin-releasing factor antagonists: therapeutic potential in the treatment of affective disorders. CNS Drugs 12:85-92.
Owens MJ. 1997. Molecular and cellular mechanisms of antidepressant drugs. Depression and Anxiety 4:153-159.
Owens MJ and Nemeroff CB. 1994. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clinical Chemistry 40:288-295.
Owens MJ and Nemeroff CB. 1991. The physiology and pharmacology of corticotropin releasing factor (CRF). Pharmacological Reviews 43:425-473.

Research Articles

Request Link Research Article
Owens MJ, Krulewicz S, Simon JS, Sheehan DV, Thase ME, Carpenter DJ, Plott SJ and Nemeroff CB. 2008. Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine. Neuropsychopharmacology (in press, Epub available).
Skelton KH, Oren D, Gutman DA, Easterlink K, Holtzman SG, Nemeroff CB and Owens MJ. 2007. The CRF1 receptor antagonist, R121919, attenuates the severity of precipitated morphine withdrawal. Eur J Pharmacology 571:17-24.
McConathy J, Capello C, Jarkas N, Stowe ZN and Owens MJ. 2007. Preparation of antidepressants for use in preclinical research. International J Neuropsychopharmacology 10:759-763.
Skelton KH, Gutman DA, Thrivikraman KV, Nemeroff CB and Owens MJ. 2007. The CRF1 receptor antagonist, R121919, attenuates the neuroendocrine and behavioral effects of precipitated lorazepam withdrawal. Psychopharmacology 192:385-396.
Geracioti TD, Carpenter L, Owens MJ, Baker DG, Ekhator NN, Sanacora G, Price LH, Strawn J, Horn PS, Kinkead B and Nemeroff CB. 2006. Elevated cerebrospinal fluid substance P concentrations in post-traumatic stress disorder and major depression. American J. Psychiatry 163:637-643.
Kinkead B, Selz KA, Owens MJ and Mandell AJ. 2006. Algorithmically designed peptides ameliorate behavioral defects in animal model of ADHD by an allosteric mechanism. J Neuroscience Methods 115:68-81.
Loughhead AM, Stowe ZN, Newport DJ, Ritchie JC, Devane CL and Owens MJ. 2006. Placental passage of tricyclic antidepressants. Biological Psychiatry 59:287-290.
C?ceda R, Kinkead B, Owens MJ and Nemeroff CB. 2005. Virally mediated increased neurotensin 1 receptor in the nucleus accumbens decreases behavioral effects of mesolimbic system activation. J. Neuroscience 25:11748-11756.
Van Ness SH, Owens MJ and Kilts CD. 2005. The variable number of tandem repeats element in dat1 regulates in vitro dopamine transporter density. BMC Genetics 6:55.
McConathy J, Owens MJ, Kilts CD, Malveaux EJ, Camp VM, Votaw JR, Nemeroff CB and Goodman MM. 2005. Synthesis and biological evaluation of trans-3-phenyl-1-indanamines as potential norepinephrine transporter imaging agents. Nuclear Medicine and Biology 32:593-605.
Garlow SJ, Boone E, Li W, Owens MJ and Nemeroff CB. 2005. Genetic analysis of the hypothalamic corticotropin-releasing factor (CRF) system. Endocrinology 146:2362-2368.
Skelton KH, Nemeroff CB and Owens MJ. 2004. Spontaneous withdrawal from the triazolobenzodiazepine alprazolam increases cortical corticotropin-releasing factor mRNA expression. J. Neuroscience 24:9303-9312.
Binder EB, Kinkead B, Owens MJ and Nemeroff CB. 2004. The neurotensin receptor antagonist SR 142948A alters Fos expression and extrapyramidal side effect profile of typical and atypical antipsychotic drugs. Neuropsychopharmacology 29:220-227.
McConathy J, Owens MJ, Kilts CD, Malveaux EJ, Camp VM, Votaw JR, Nemeroff CB and Goodman MM. 2004. Synthesis and biological evaluation of [11C]talopram and [11C]talsupram: candidate PET ligands for the norepinephrine transporter. Nuclear Medicine and Biology 31:705-718.
Selz KA, Mandell AJ, Shlesinger MF, Acuragi V and Owens MJ. 2004. Designing human M1 muscarinic receptor-targeted hydrophobic eigenmode-matched peptides as functional modulators. Biophysical Journal 86:1308-1331.
Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J and Owens MJ. 2004. Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biological Psychiatry 55:320-322.
Gutman DG, Owens MJ and Nemeroff CB. 2003. The corticotropin-releasing factor1 receptor antagonist R121919 attenuates the behavioral and endocrine responses to stress. J. Pharmacology & Experimental Therapeutics 304:874-880.
Gilmor ML, Skelton KH, Nemeroff CB and Owens MJ. 2003. The effects of chronic treatment with the mood stabilizers valproic acid and lithium on corticotropin-releasing factor neuronal systems. J. Pharmacology & Experimental Therapeutics 305:434-439.
Gilmor M, Owens MJ and Nemeroff CB. 2002. Inhibition of the norepinephrine transporter in depressed patients treated with paroxetine. American Journal of Psychiatry 159:1702-1710.
Mandell AJ, Selz KA, Owens MJ, Kinkead B, Shlesinger MF, Gutman DA and Arcuragi V. 2003. Cellular and behavioral effects of the D2 dopamine receptor hydrophobic eigenmode-targeted peptide ligands. Neuropsychopharmacology 28:S98-S107.
Stout SC, Owens MJ and Nemeroff CB. 2002. Regulation of CRF gene expression and peptide concentrations by stress and chronic antidepressant treatment. J. Pharmacology & Experimental Therapeutics 300:1085-1092.
Owens MJ, Knight BS and Nemeroff CB. 2001. Second generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biological Psychiatry 50:345-350.
Martarello L, Kilts CD, Ely T, Owens MJ, Nemeroff CB, Camp M and Goodman MM. 2001. Synthesis and characterization of fluorinated and iodinated pyrrolopyrimidines as PET/SPECT ligands for the CRF1 receptor. Nuclear Medicine and Biology 28:187-195.
Binder E, Kinkead B, Owens MJ, Kilts CD and Nemeroff CB. 2001. Enhanced neurotensin neurotransmission is involved in the clinically relevant behavioral effects of antipsychotic drugs: evidence from animal models of sensorimotor gating. J Neuroscience 21:601-608.
Skelton KH, Nemeroff CB and Owens MJ. 2000. A comparison of plasma alprazolam concentrations following different routes of chronic administration in the Sprague-Dawley rat: implications for psychotropic drug research. Psychopharmacology 151:72-76.
Owens MJ, Knight DL and Nemeroff CB. 2000. Paroxetine binding to the rat norepinephrine transporter in vivo. Biological Psychiatry 47:842-845.
Skelton KH, Nemeroff CB, Knight DL and Owens MJ. 2000. Chronic administration of the triazolobenzodiazepine alprazolam: bioavailability and opposite regulation of corticotropin-releasing factor and urocortin systems. J. Neuroscience 20:1240-1248.
Arborelius L, Owens MJ, Plotsky PM and Nemeroff CB. 1999. The role of corticotropin-releasing factor (CRF) in depression and anxiety disorders. J. Endocrinology 160:1-12.
Stowe ZN and Owens MJ. 1998. Use of psychotropic medications during lactation. American Journal of Psychiatry. 155:1626-1627.
Radke JM, Owens MJ, Ritchie JC and Nemeroff CB. 1998. Chronic administration of antipsychotic drugs increases neurotensin efflux in dopamine terminal regions: selective effects of the atypical antipsychotics, clozapine and olanzapine. Proc. Natl. Acad. Sci. USA 95:11462-11464.
Mandell AJ, Owens MJ, Selz KA, Morgan WN, Shlesinger MF and Nemeroff CB. 1998. Differential modulation of ligand association kinetics by hydrophobic mode-matched neuropeptides. Biopolymers 46:89-101.
Owens MJ, Morgan WN, Plott S and Nemeroff CB. 1997. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J. Pharmacology and Experimental Therapeutics 283:1305-1322.
Pariante C, Pearce BD, Owens MJ and Miller AJ. 1997. Steroid-independent translocation of the glucocorticoid receptor induced by the antidepressant desipramine. Molecular Pharmacology 52:571-581.
Stowe ZN, Owens MJ, Landry JC, Kilts CD, Ely T, Llewellyn A and Nemeroff CB. 1997. Excretion of sertraline in human breast milk and nursing infants. American J. Psychiatry 154:1255-1260.
Owens MJ, Ballenger CA, Knight DL and Nemeroff CB. 1996. Platelet 5-HT transporter and 5-HT2A receptor binding following chronic hypercorticosteronemia, neurotoxin-induced depletion of 5-HT, or DOI administration in the rat. J. Pharmacology and Experimental Therapeutics 278:1040-1049.
Coplan JD, Andrews MW, Rosenblum LA, Owens MJ, Friedman S, Gorman JM and Nemeroff CB. 1996. Persistent elevations of cerebrospinal fluid concentrations of corticotropin-releasing factor in adult nonhuman primates exposed to early life stressors: implications for the pathophysiology of mood and anxiety disorders. Proc. Natl. Acad. Sci. USA 93:1619-1623.
Ladd CO, Owens MJ and Nemeroff CB. 1996. Persistent changes in corticotropin-releasing factor neuronal systems induced by maternal deprivation. Endocrinology 137:1212-1218.
Owens MJ, Mulchahey JJ, Kasckow JW, Plotsky PM and Nemeroff CB. 1995. Exposure to an antisense oligonucleotide decreases CRF receptor binding in rat pituitary cultures. J Neurochemistry 64:2358-2361.
Owens MJ, Ritchie JC and Nemeroff CB. 1992. 5?-pregnane-3?, 21-diol-20-one (THDOC) attenuates mild stress-induced increases in plasma corticosterone via a non-glucocorticoid mechanism: comparison with alprazolam. Brain Research 573:353-355.
Owens MJ, Vargas MA, Knight DL and Nemeroff CB. 1991. The effects of alprazolam on corticotropin-releasing factor neurons in the rat brain: acute time course, chronic treatment and abrupt withdrawal. J. Pharmacology and Experimental Therapeutics 258:349-356.
Owens MJ, Knight DL, Ritchie JC and Nemeroff CB. 1991. The 5 HT2 agonist (?) 1 (2,5 dimethoxy 4 bromophenyl) 2 aminopropane (DOB) stimulates the hypothalamic pituitary adrenal (HPA) axis: II. Biochemical and physiological evidence for the development of tolerance after chronic administration. J. Pharmacology and Experimental Therapeutics 256:795-800.
Owens MJ, Knight DL, Ritchie JC and Nemeroff CB. 1991. The 5 HT2 agonist (?) 1 (2,5 dimethoxy 4 bromophenyl) 2 aminopropane (DOB) stimulates the hypothalamic pituitary adrenal axis: I. Acute effects on HPA axis activity and corticotropin releasing factor (CRF) containing neurons in the rat brain. J. Pharmacology and Experimental Therapeutics 256:787-794.
Nemeroff CB, Owens MJ, Bissette G, Andorn AC and Stanley M. 1988. Reduced corticotropin releasing factor (CRF) binding sites in the frontal cortex of suicides. Archives of General Psychiatry 45:577 579.